News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for November 2016 Shelley Wood November 30, 2016
News Daily News Tricky Population of Patients With A-fib Undergoing PCI Tackled in New Consensus Document Todd Neale November 29, 2016
News Conference News AHA 2016 My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial Shelley Wood November 28, 2016
News Conference News AHA 2016 Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI Todd Neale November 14, 2016
Presentation TCT 2016 TCT 53: Thromboembolic Event Rate Is Elevated With Lower Adherence to Warfarin and NOACs Presenter: Neal S. Kleiman, David F. Kong, Jeffrey R Winterfield October 31, 2016
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for October 2016 Caitlin E. Cox October 29, 2016
News Daily News Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge Todd Neale October 18, 2016
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for August 2016 Caitlin E. Cox September 01, 2016
News Conference News EuroPCR 2016 EWOLUTION Confirms Safety, Efficacy for Real-World Use of Watchman, Even With No Postprocedural Drug Therapy Yael L. Maxwell May 17, 2016
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for April 2016 Shelley Wood April 29, 2016
News Daily News Good Warfarin Management Prevents Complications in A-fib Patients, Swedish Study Contends L.A. McKeown April 21, 2016
Presentation Scripps 2016 Putting It All Together: Warfarin, NOAC or LAA Closure? Presenter: Brian K. Whisenant February 04, 2016
News Daily News In the Real World, Dabigatran and Warfarin Give Equal Stroke Protection to A-fib Patients Todd Neale January 25, 2016
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular News Stories for 2015 Shelley Wood December 29, 2015
News Opinion Editor's Corner Las 10 Noticias de TCTMD Más Leídas de 2015 Shelley Wood December 29, 2015
News Industry News Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate) November 29, 2015
News Daily News First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions Todd Neale October 26, 2015
News Daily News Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones Todd Neale October 26, 2015
News Industry News CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®) September 25, 2015